(Albany, United States) As per DelveInsight’s assessment, globally, the Uveitis pipeline constitutes 15+ key companies continuously working towards developing 15+ Uveitis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.

 

In the Uveitis Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Uveitis clinical trials studies, Uveitis NDA approvals (if any), and product development activities comprising the technology, Uveitis collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

To explore more information on the latest breakthroughs in the Uveitis pipeline treatment landscape of the report, click here @ Uveitis Pipeline Outlook

 

Key Takeaways from the Uveitis Pipeline Report

• DelveInsight’s Uveitis Pipeline analysis depicts a robust space with 15+ active players working to develop 15+ pipeline treatment therapies.
• The leading Uveitis Companies working in the market include Eli Lilly and Company, Santen Inc., Clearside Biomedical, Affibody, Eyevensys, Alcon Research, Panoptes Pharma GmbH, Tarsier Pharma, Eye Pharma, Apitope Technology, Mitotech, and others
• Promising Uveitis Pipeline Therapies in the various stages of development include Izokibep, Adalimumab, Predinisone, Fluocinolone Acetonide Intravitreal Implant 0.18 mg, QLETLI, Izokibep, Prednisone/Prednisolone, Baricitinib, Sarilumab, Methotrexate, and others.
• On June 2023, ACELYRIN Inc announced a study of phase 2 clinical trials for Izokibep. Izokibep is a small protein molecule that acts as a selective, potent inhibitor of interleukin-17A, to which it binds with high affinity. This study investigates izokibep in subjects with active non-infectious, intermediate-, posterior- or pan-uveitis requiring high-dose steroids.
• On April 2023, Bio-Thera Solutions announced a study of phase 4 clinical trials for QLETLI. This is a multicenter, prospective, post-marketing clinical study with a total of 60 uveitis (UV) subjects planned to be enrolled.
• On February 2023, ACELYRIN Inc announced a study of phase 2 clinical trials for Izokibep. This is a multicenter, phase 2 trial to explore the efficacy and safety of Izokibep (ABY-035) in treating disease activity in patients with non-Infectious Intermediate, Posterior, Pan-Uveitis with significant disease activity at BL despite treatment with stable doses of corticosteroids (≥7 to ≤40 mg/day oral prednisolon or equivalent).

 

Uveitis Overview

Uveitis is a general term describing a group of inflammatory diseases that produces swelling and destroys eye tissues. These diseases can slightly reduce vision or lead to severe vision loss. Uveitis is swelling of the middle layer of the eye, which is called the uvea.

 

To explore more information on the latest breakthroughs in the Uveitis Pipeline treatment landscape of the report, click here @ https://www.delveinsight.com/sample-request/uveitis-pipeline-insight

 

Uveitis Emerging Drugs Profile

• Barcitinib: Eli Lilly and Company
• EYS606: Eyevensys

 

Uveitis Pipeline Therapeutics Assessment

There are approx. 15+ Uveitis companies which are developing the therapies for Uveitis. The Uveitis companies which have their Uveitis drug candidates in the most advanced stage, i.e. Phase III include, Eli Lilly and Company.

 

Request a sample and discover the recent advances in Uveitis Ongoing Clinical Trial Analysis and Medications, click here @ https://www.delveinsight.com/sample-request/uveitis-pipeline-insight

 

Uveitis Drugs and Companies

• Izokibep: AcelyRin Inc
• Adalimumab: AbbVie
• Prednisone: Abbott
• Fluocinolone Acetonide Intravitreal Implant 0.18 mg: EyePoint Pharmaceuticals Inc
• QLETLI: Bio-Thera Solutions

 

Uveitis Therapeutics Assessment

• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

 

Some of the Companies in the Uveitis Therapeutics Market include-

Eli Lilly and Company, Santen Inc., Clearside Biomedical, Affibody, Eyevensys, Alcon Research, Panoptes Pharma GmbH, Tarsier Pharma, Eye Pharma, Apitope Technology, Mitotech, and others

 

Dive deep into rich insights for drugs for Uveitis Pipeline, click here for Uveitis Unmet Needs and Analyst Views @ https://www.delveinsight.com/sample-request/uveitis-pipeline-insight

 

Scope of the Uveitis Pipeline Report

• Coverage- Global
• Uveitis Companies- Eli Lilly and Company, Santen Inc., Clearside Biomedical, Affibody, Eyevensys, Alcon Research, Panoptes Pharma GmbH, Tarsier Pharma, Eye Pharma, Apitope Technology, Mitotech, and others
• Uveitis Pipeline Therapies- Izokibep, Adalimumab, Predinisone, Fluocinolone Acetonide Intravitreal Implant 0.18 mg, QLETLI, Izokibep, Prednisone/Prednisolone, Baricitinib, Sarilumab, Methotrexate, and others.
• Uveitis Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Uveitis Merger and acquisitions, Licensing Activities @ https://www.delveinsight.com/sample-request/uveitis-pipeline-insight

 

Table of Content

1. Introduction
2. Executive Summary
3. Uveitis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. Baricitinib: Eli Lilly and Company
8. Drug profiles in the detailed report…..
9. Mid Stage Products (Phase II)
10. EYS606: Eyevensys
11. Drug profiles in the detailed report…..
12. Early stage products (Phase I/II)
13. TRS01: Tarius Pharma
14. Drug profiles in the detailed report…..
15. Inactive Products
16. Uveitis Key Companies
17. Uveitis Key Products
18. Uveitis- Unmet Needs
19. Uveitis- Market Drivers and Barriers
20. Uveitis- Future Perspectives and Conclusion
21. Uveitis Analyst Views
22. Uveitis Key Companies
23. Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services